Scarica l'app Stockscreener
5.11
5.00%
0.27
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NEO Giù?
Forum
Previsione
Frazionamento azionario
Neogenomics Inc Borsa (NEO) Ultime notizie
Earnings Release: Here's Why Analysts Cut Their NeoGenomics, Inc. (NASDAQ:NEO) Price Target To US$8.72 - Yahoo.co
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc.NEO - PR Newswire
Is NeoGenomics Inc. a growth stock or a value stockWealth Building Watchlist For Every Investor - jammulinksnews.com
What catalysts could drive NeoGenomics Inc. stock higher in 2025AI Powered Growth Plan For 2025 - jammulinksnews.com
NeoGenomics, Inc. (NASDAQ:NEO) Q2 2025 Earnings Call Transcript - Insider Monkey
NeoGenomics outlines revised 2025 outlook with 9%-10% revenue growth target amid pharma headwinds and PanTracer launch - MSN
NeoGenomics Earnings Call: Growth Amid Challenges - TipRanks
Why NeoGenomics Inc. stock attracts strong analyst attentionTop Gaining Picks With Entry Signals Identified - metal.it
Analyzing recovery setups for NeoGenomics Inc. investorsLow Drawdown Real Time Trading Tips Shared - metal.it
Market Cool On NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues Pushing Shares 27% Lower - simplywall.st
Momentum Traders Eye NeoGenomics Inc. for Quick BounceVerified Signal From Chart Patterns Detected - beatles.ru
NeoGenomics (NEO) Meets Q2 Earnings Estimates - MSN
Down 29.2% in 4 Weeks, Here's Why NeoGenomics (NEO) Looks Ripe for a Turnaround - Yahoo Finance
It's Down 27% But NeoGenomics, Inc. (NASDAQ:NEO) Could Be Riskier Than It Looks - 富途牛牛
NeoGenomics Inc. stock daily chart insightsShort Term Setup With Predictive Chart Confirmed - metal.it
NeoGenomics launches blood-based cancer profiling test for solid tumors - Investing.com Australia
NeoGenomics launches blood-based cancer profiling test for solid tumors By Investing.com - Investing.com India
NeoGenomics revenue up 10% to USD 181m in Q2 2025 - Medical Buyer
NeoGenomics Targets $5B Market with Revolutionary Blood-Based Cancer Gene Test PanTracer LBx - Stock Titan
NeoGenomics Second Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
Neogenomics stock rating downgraded to Neutral by BTIG on execution concerns - Investing.com Canada
Government of Canada partners with United Kingdom to invest in groundbreaking AI alignment research - The Globe and Mail
NeoGenomics Reports Second Quarter 2025 Results - BioSpace
NeoGenomics Inc (NEO) Q2 2025 Earnings Call Highlights: Navigating Growth Amidst Pharma Challenges - Investing.com Canada
Neogenomics 2025 Q2 Earnings Misses Targets as Net Loss Worsens by 141.9% - AInvest
NeoGenomics Reports Revenue Growth Amid Rising Losses - TipRanks
Is NeoGenomics Inc. the Top Chart Pick This WeekLow Risk Equity Screener With Results Shared - metal.it
Neogenomics: William Blair downgrades to 'Market Perform' Rating - AInvest
NeoGenomics Stock Falls 20.2% After Lowered Financial GuidanceNews and Statistics - IndexBox
Neogenomics stock price target lowered to $8 at Needham on weak guidance - Investing.com Canada
Neogenomics Plunges 20.9%—What’s Fueling This Volatility? - AInvest
Why NeoGenomics (NEO) Shares Are Falling Today - Yahoo Finance
NeoGenomics: Q2 Earnings Snapshot - The Washington Post
William Blair downgrades Neogenomics stock rating to Market Perform By Investing.com - Investing.com Canada
Earnings call transcript: NeoGenomics Q2 2025 sees EPS beat, stock drops - Investing.com Australia
NeoGenomics: Navigating Short-Term Pain for Long-Term Gain in Oncology Diagnostics - AInvest
Earnings call transcript: NeoGenomics Q2 2025 sees EPS beat, stock drops By Investing.com - Investing.com South Africa
NeoGenomics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:NEO) - Seeking Alpha
Neogenomics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
NeoGenomics Q2 2025 slides: Revenue grows 10% but guidance cut sparks selloff By Investing.com - Investing.com South Africa
NeoGenomics shares plunge on slashed revenue guidance - Investing.com
Is NeoGenomics (NEO) a Buy After Missing Q2 Guidance? Assessing Long-Term Growth Potential Amid Short-Term Earnings Disappointments in the Oncology Diagnostics Sector - AInvest
NeoGenomics earnings beat, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Why Did Neogenomics Plunge 15.94% Despite Beating EPS Estimates? - AInvest
NeoGenomics (NASDAQ:NEO) Misses Q2 Sales Targets, Stock Drops 15.8% - Yahoo Finance
NEOGENOMICS INC SEC 10-Q Report - TradingView
Candlestick Reversal Detected on NeoGenomics Inc.’s ChartHigh Growth Low Risk Stock Selection Gets Analyst Nod - metal.it
NeoGenomics Wants Jury Trial In Natera DNA Test Patent Fight - Law360
What is NeoGenomics Inc. company’s growth strategyBreakout Stocks Tips That Work - jammulinksnews.com
What institutional investors are buying NeoGenomics Inc. stockBreakout Stocks Signals For Fast Growth - jammulinksnews.com
NeoGenomics (NEO): Is This a Buy-the-Dip Opportunity in the Precision Oncology Diagnostics Sector? - AInvest
NeoGenomics Q2 2025 Earnings Preview - MSN
When is NeoGenomics Inc. stock expected to show significant growthGet expert analysis on top stock picks - jammulinksnews.com
What are the latest earnings results for NeoGenomics Inc.Strong return on assets - jammulinksnews.com
How many analysts rate NeoGenomics Inc. as a “Buy”Achieve rapid portfolio growth with expert help - jammulinksnews.com
How volatile is NeoGenomics Inc. stock compared to the marketBuild wealth faster with consistent growth stocks - jammulinksnews.com
NeoGenomics (NEO): A Buy-the-Dip Opportunity in Oncology Diagnostics or a Risky Bet? - AInvest
NeoGenomics (NEO) Reports Q2: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
0.94%
1.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):